1,106 results on '"Schuitemaker, Hanneke"'
Search Results
2. CoPoP liposomes displaying stabilized clade C HIV-1 Env elicit tier 2 multiclade neutralization in rabbits
3. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
4. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
5. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial
6. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
7. Enhancing breadth and durability of humoral immune responses in non-human primates with an adjuvanted group 1 influenza hemagglutinin stem antigen
8. Combination Ad26.RSV.preF/preF protein vaccine induces superior protective immunity compared with individual vaccine components in preclinical models
9. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
10. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2
11. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
12. Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
13. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques
14. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques
15. Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice
16. Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets
17. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
18. Impact of SARS-CoV-2 spike stability and RBD exposure on antigenicity and immunogenicity
19. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
20. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
21. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
22. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)
23. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
24. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
25. SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
26. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
27. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption
28. Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
29. First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
30. Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses
31. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.
32. Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
33. Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
34. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
35. In vivo HIV-1 Infection of CD45RA + CD4 + T Cells Is Established Primarily by Syncytium-Inducing Variants and Correlates with the Rate of CD4 + T Cell Decline
36. Inactivated Viral Vaccines
37. Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load
38. Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
39. Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPV
40. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats
41. Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
42. Booster immunization with Ad26.COV2.S or Omicron adapted vaccine enhanced immune responses and efficacy against SARS-CoV-2 Omicron in non-human primates
43. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys
44. Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
45. Characterisation of long-term non-progression of HIV-1 infection after seroconversion: a cohort study
46. Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models
47. Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
48. Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
49. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer
50. Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.